title: What are the latest advancements in acute myeloid leukemia therapy?
authors.affiliation: Department of Medicine, Division of Blood & Marrow Transplantation, University of California, San Diego Moores Cancer Center, San Diego, CA, USA.|Department of Medicine, Division of Hematology/Oncology, University of California, San Diego Moores Cancer Center, San Diego, CA, USA.
authors.forename: Aaron
authors.initials: A
authors.lastname: Goodman
authors.affiliation: Department of Medicine, Division of Blood & Marrow Transplantation, University of California, San Diego Moores Cancer Center, San Diego, CA, USA.
authors.forename: Edward D
authors.initials: ED
authors.lastname: Ball
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003845:Deoxycytosine Nucleotides / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007167:Immunotherapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000473:pathology; D058990:Molecular Targeted Therapy; D054852:Small Molecule Libraries / Q000627:therapeutic use*; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors / Q000276:immunology / Q000627:therapeutic use
chemical_list: D003845:Deoxycytosine Nucleotides; D018796:Immunoconjugates; D054852:Small Molecule Libraries; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3
keywords: AML; antibody–drug conjugates; targeted agents; therapy